Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your Swiss-Rx-Login. For further information please see the FAQ.
EXKIVITY Kaps 40 mg 112 Stk
Drug
Exkivity, Hartkapseln
nicht-resezierbares oder metastasiertes nicht-kleinzelliges Lungenkarzinom (NSCLC) mit Exon- 20-Insertionsmutation des epidermalen Wachstumsfaktor-Rezeptors (EGFR)
07.16. – oncologicals
HAM – Human medicine
KAHA – Capsule, hard
S – synthetic products for human use
A – Dispensed once only on prescription by a physician or veterinarian (A)
B – limited
6/1/2022
5/31/2024
Dosage strength
Exkivity 40 mg, Hartkapseln
nicht-resezierbares oder metastasiertes nicht-kleinzelliges Lungenkarzinom (NSCLC) mit Exon- 20-Insertionsmutation des epidermalen Wachstumsfaktor-Rezeptors (EGFR)
01
B – limited
Package
7680681470014
No information made available
A/R – Authorised / referenced
112 capsule(s)
001
B – limited
Declaration
Component
40 mg mobocertinibum
48.06 mg mobocertinibi succinas
48.06 mg mobocertinibi succinas
gelatina
E 171
lacca
propylenglycolum
E 172 (nigrum)
kalii hydroxidum
E 171
lacca
propylenglycolum
E 172 (nigrum)
kalii hydroxidum
Spezialitätenliste***
SL
-
-
8974.95
None
Yes
10%
No
Authorisation holder
7601001325050
Takeda Pharma AG
8152 Opfikon (ZH)
8152 Opfikon (ZH)
Date of revision of the text
4/4/2024
Please log in as a company employee using your Swiss-Rx-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.